Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 8/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131394 | 1.00 | MAPK1 (0.54) | MAPK1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4131399 | 1.00 | MAPK1 (0.54) | MAPK1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4133330 | 0.90 | MAPK1 (0.62) | MAPK1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4133333 | 0.90 | MAPK1 (0.62) | MAPK1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4133327 | 0.90 | MAPK1 (0.62) | MAPK1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4132886 | 0.87 | MAPT (0.64) | MAPK1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4132883 | 0.87 | MAPT (0.64) | MAPK1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4129781 | 0.85 | CTNNB1 (0.58) | MAPK1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4129778 | 0.85 | CTNNB1 (0.58) | MAPK1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4130332 | 0.83 | MAPK1 (0.60) | MAPK1MEN1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20090247516-A1 | 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS | KOTNIK MIHA | 2009-10-01 | — | — | US | disclosed |
| US-20090247516-A1 | 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS | KOTNIK MIHA | 2009-10-01 | — | — | US | disclosed |
| US-20090247516-A1 | 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS | KOTNIK MIHA | 2009-10-01 | — | — | US | disclosed |
| EP-1916249-A1 | 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents | LEK Pharmaceuticals D.D. (SI) | 2008-04-30 | — | — | EP | disclosed |
| EP-1916249-A1 | 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents | LEK Pharmaceuticals D.D. (SI) | 2008-04-30 | — | — | EP | disclosed |
| WO-2008043733-A1 | 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS | LEK PHARMACEUTICAL D.D. (SI) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | MAPK1 2158/4885MEN1 846/4885KMT2A 470/4885 |
| US-20090247516-A1 | 3- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS | XDH, TXLNA, Q6ZSR9 | MAPK1 3035/4885MEN1 2336/4885KMT2A 1459/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | MAPK1 2158/4885MEN1 846/4885KMT2A 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.